(24/7 MARKET NEWS) – Nuwellis, Inc. (Nasdaq: NUWE) is trading higher in this morning’s premarket after publishing key clinical data supporting the use of ultrafiltration with its Aquadex FlexFlow(R) System in high-risk postoperative coronary artery bypass grafting (CABG) patients in the Journal of Cardiac Surgery.
The commercial-stage company is now trading at $1.01, up $0.380 (+60.29%), on over & million shares traded.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.